Abingdon Health Plc
ABDX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.00 | 1.26 | -0.39 |
| FCF Yield | -4.86% | -7.83% | -1.51% | -3.64% |
| EV / EBITDA | -53.53 | -10.67 | 117.61 | -36.02 |
| Quality | ||||
| ROIC | -22.81% | -29.56% | -1.26% | -42.40% |
| Gross Margin | 41.44% | 29.64% | 60.67% | 53.03% |
| Cash Conversion Ratio | 1.07 | 0.85 | 6.97 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.82% | 16.53% | 2,167,184.50% | 1,964,787.15% |
| Free Cash Flow Growth | 40.52% | -351.15% | 60.81% | -11.24% |
| Safety | ||||
| Net Debt / EBITDA | 1.87 | 1.14 | -1.47 | 1.10 |
| Interest Coverage | -32.30 | -58.98 | -5.22 | -36.85 |
| Efficiency | ||||
| Inventory Turnover | 5.94 | 4.90 | 3.32 | 2.75 |
| Cash Conversion Cycle | 38.43 | -16.83 | 16.09 | -89.03 |